Extended Data Fig. 9: Kaplan-Meier plots of OS by presence of top acquired alterations (top panel) or MET amplification (bottom panel) following treatment with Enco+Cetux±Bini. | Nature Medicine

Extended Data Fig. 9: Kaplan-Meier plots of OS by presence of top acquired alterations (top panel) or MET amplification (bottom panel) following treatment with Enco+Cetux±Bini.

From: Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial

Extended Data Fig. 9: Kaplan-Meier plots of OS by presence of top acquired alterations (top panel) or MET amplification (bottom panel) following treatment with Enco+Cetux±Bini.

Cox proportional hazard models with and without adjustment of baseline covariates (ECOG performance status, C-reactive protein, number of organs, tumor status, cetuximab source, and prior use of irinotecan at randomization) were used. Bini, binimetinib; Cetux, cetuximab; CI, confidence interval; Enco, encorafenib; HR hazard ratio; OS, overall survival.

Back to article page